The Trump administration's healthcare policy changes from the gutting of medical research grants to changes on the CDC vaccine board were the focus of the discussion on the latest episode of the ...

Rural hospitals are facing growing cybersecurity threats and digital demands but often lack the resources to respond — a gap ...

June has seen a slew of executive hires, promotions, exits and layoffs across the healthcare sector. For example, CVS Health ...

The Supreme Court upheld the constitutionality of an Affordable Care Act provision requiring insurance coverage of certain preventive services without cost-sharing. Many healthcare leaders applauded ...

Hinge Health and Omada Health. During a recent panel discussion, venture capitalists shared lessons learned about health tech ...

The resilience of Medicaid lies in its complexity. It has resisted large-scale restructuring because it is interwoven with public and private delivery systems. That same complexity now demands a ...

Bristol Myers Squibb is buying into this strategy, paying BioNTech $1.5 billion up front to collaborate on BNT327’s development. Each company may also test drugs from their own pipelines in ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs ...

The Trump administration’s cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu viruses is the latest blow to national defense, former health ...

Hospitals saw improved financial performance during the first four months of the year, with operating margins rising to 3.3% thanks to higher patient volumes and more efficient throughput. However ...

California’s SB553, the nation’s first comprehensive and multi-industry workplace violence prevention law, has been in effect for almost a year. Many other states are following suit with their ...

Trump said this policy change is needed because high drug prices in the U.S. subsidize low drug prices in foreign markets, an imbalance that amounts to other countries getting a “free ride ...